Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, discusses the management of adverse events associated with the use of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML), such as dose adjustments associated with pleural effusions or elevation of transaminases. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.